Texto completo (165)
- Antivirales (162)
- Subtipo H1N1 del Virus de la Influenza A (119)
- Gripe Humana (118)
- Virus de la Influenza A (38)
- Farmacorresistencia Viral (28)
- Infecciones por Orthomyxoviridae (24)
- Oseltamivir (24)
- Brotes de Enfermedades (22)
- Pandemias (17)
- Subtipo H3N2 del Virus de la Influenza A (14)
- Subtipo H5N1 del Virus de la Influenza A (13)
- Virus de la Influenza B (12)
- Vacunas contra la Influenza (9)
- Zanamivir (9)
- Gripe Aviar (7)
- Replicación Viral (6)
- Pautas en la Práctica de los Médicos (6)
- Neuraminidasa (6)
- Orthomyxoviridae (5)
- Proteínas Virales (5)
- Mostrar más...
- Antiviral Res (18)
- PLoS One (12)
- Influenza Other Respir Viruses (10)
- Clin Infect Dis (7)
- J Infect Dis (7)
- J Virol (7)
- J Immunol (5)
- Antibiot Khimioter (4)
- Antimicrob Agents Chemother (4)
- J Virol Methods (4)
- Vopr Virusol (4)
- J Clin Virol (3)
- J Gen Virol (3)
- PLoS Curr (3)
- Am J Public Health (2)
- Bioorg Med Chem Lett (2)
- Clin Nurse Spec (2)
- Expert Rev Respir Med (2)
- J Antimicrob Chemother (2)
- J Clin Microbiol (2)
- Mostrar más...
Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic.
Fuente: Antimicrob Resist Infect Control;3(1): 2, 2014.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24405855
Resumen: BACKGROUND: Multiple observational studies have associated antiviral treatment of patients hospitalized with influenza with improved outcome, including reduced mortality. During the 2009-2010 H1N1 pandemic increased use of antiviral treatment of hospital patients was reported. We have carried out prospective surveillance for influenza in patients in a large network of Canadian hospitals since 2006. We wished to assess trends in antiviral use in the two seasons (2010-2011 and 2011-2012) sinc (mas)
Impact of medical and behavioural factors on influenza-like illness, healthcare-seeking, and antiviral treatment during the 2009 H1N1 pandemic: USA, 2009-2010.
Fuente: Epidemiol Infect;142(1): 114-25, 2014 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23522400
Resumen: We analysed a cross-sectional telephone survey of U.S. adults to assess the impact of selected characteristics on healthcare-seeking behaviours and treatment practices of people with influenza-like illness (ILI) from September 2009 to March 2010. Of 216,431 respondents, 8.1% reported ILI. After adjusting for selected characteristics, respondents aged 18-64 years with the following factors were more likely to report ILI: a diagnosis of asthma [adjusted odds ratio (aOR) 1.88, 95% CI 1.67-2.13 (mas)
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Fuente: Antiviral Res;100(2): 356-64, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24055835
Resumen: Neuraminidase inhibitors (NAIs) play vital roles in controlling human influenza epidemics and pandemics. However, the emergence of new human influenza virus mutant strains resistant to existing antiviral drugs has been becoming a major challenge. Therefore, it is critical to uncover the mechanisms of drug resistance and seek alternative treatments to combat drug resistance. In this study, molecular dynamics (MD) simulations and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) wer (mas)
Estimated impact of aggressive empirical antiviral treatment in containing an outbreak of pandemic influenza H1N1 in an isolated First Nations community.
Fuente: Influenza Other Respir Viruses;7(6): 1409-15, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23879801
Resumen: BACKGROUND: The 2009 influenza A (H1N1) pandemic was mild by historical standards, but was more severe in isolated Canadian Indigenous communities. Oseltamivir was used aggressively for outbreak control in an isolated northern Ontario First Nations community. We used mathematical modeling to quantify the impact of antiviral therapy on the course of this outbreak. METHODS: We used both a Richards growth model and a compartmental model to evaluate the characteristics of the outbreak based on (mas)
Fuente: Influenza Other Respir Viruses;7(6): 1427-32, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23957666
Resumen: BACKGROUND: The World Health Organization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness. OBJECTIVES: The aim of this study was to determine the proportion of cases with laboratory-confirmed A(H1N1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (H1N1) 2009 and to investigate factors associated with the use of antivirals. METHODS: We analyzed cases with laboratory-confirmed A (mas)
Fuente: Influenza Other Respir Viruses;7 Suppl 3: 18-23, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24215378
Resumen: Neuraminidase inhibitors (NAIs) are first-line agents for the treatment and prevention of influenza virus infections. As for other antivirals, the development of resistance to NAIs has become an important concern particularly in the case of A(H1N1) viruses and oseltamivir. The most frequently reported change conferring oseltamivir resistance in that viral context is the H275Y neuraminidase mutation (N1 numbering). Recent studies have shown that, in the presence of the appropriate permissive (mas)
Fuente: J Antimicrob Chemother;68(10): 2324-31, 2013 Oct.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23759670
Resumen: OBJECTIVE: To perform antiviral susceptibility monitoring of treated individuals in the community during the 2009 influenza A(H1N1) pandemic in England. PATIENTS AND METHODS: Between 200 and 400 patients were enrolled daily through the National Pandemic Flu Service (NPFS) and issued with a self-sampling kit. Initially, only persons aged 16 and over were eligible, but from 12 November (week 45), self-sampling was extended to include school-age children (5 years and older). All samples receiv (mas)
Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection.
Fuente: Jpn J Infect Dis;66(5): 425-7, 2013.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24047743
Resumen: The 2009 pandemic influenza A (H1N1) was a considerable public health concern worldwide. Significant morbidity and mortality were observed in complicated cases, despite the early administration of neuramidase inhibitors. The limitations of neuramidase inhibitor monotherapy have renewed interest in combination antiviral therapy or higher-dose oseltamivir therapy. Herein, we report our clinical experience and virological outcomes with high-dose oseltamivir or combination antiviral therapy in (mas)
Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.
Fuente: Clin Exp Rheumatol;31(5): 723-30, 2013 Sep-Oct.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23806224
Resumen: OBJECTIVES: Booster vaccination against 2009 H1N1 influenza virus was recommended for rheumatologic patients under immunosuppressive therapy during the 2009/2010 H1N1 pandemic. In this study we assessed whether B cell depletion with rituximab influences of the antiviral immune response in 2009 H1N1 influenza virus-vaccinated patients. METHODS: Influenza virus-specific immune responses were analysed after the first and a booster vaccination with pandemrixTM in sixteen consecutive rituximab-t (mas)
Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection.
Fuente: Acta Pharmacol Sin;34(8): 1075-83, 2013 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23770981
Resumen: AIM: To investigate the effects of arbidol hydrochloride (ARB), a widely used antiviral agent, on the inflammation induced by influenza virus. METHODS: MDCK cells were infected with seasonal influenza A/FM/1/47 (H1N1) or pandemic influenza A/Hubei/71/2009 (H1N1). In vitro cytotoxicity and antiviral activity of ARB was determined using MTT assay. BALB/c mice were infected with A/FM/1/47 (H1N1). Four hours later the mice were administered ARB (45, 90, and 180 mg·kg(-1)·d(-1)) or the neurami (mas)
Fuente: Evid Based Complement Alternat Med;2013: 729081, 2013.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23935676
Resumen: The new antiviral activity of the protein extracted from Momordica charantia was determined with different subtypes of influenza A. The protein was purified from the seed of M. charantia using an anion exchanger and a Fast Protein Liquid Chromatography (FPLC) system. At the concentration of 1.401 mg/mL, the protein did not exhibit cytotoxicity in Madin-Darby canine kidney cells (MDCK) but inhibited 1 × 10(5) FFU influenza A/PR/8/34 H1N1 virus at 56.50%, 65.72%, and 100% inhibition by the p (mas)
Antiviral responses by Swine primary bronchoepithelial cells are limited compared to human bronchoepithelial cells following influenza virus infection.
Fuente: PLoS One;8(7): e70251, 2013.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23875024
Resumen: Swine generate reassortant influenza viruses because they can be simultaneously infected with avian and human influenza; however, the features that restrict influenza reassortment in swine and human hosts are not fully understood. Type I and III interferons (IFNs) act as the first line of defense against influenza virus infection of respiratory epithelium. To determine if human and swine have different capacities to mount an antiviral response the expression of IFN and IFN-stimulated genes (mas)